The current findings on the role of MKP-1 in bleomycin-induced fibrosis also shed light on the hitherto unknown mechanisms of the antifibrotic effects of cGMP-enhancers, namely the sGC stimulator riociguat and PDE5 inhibitors, recommended currently to the treatment of SSc-related disease subtypes [46]. The gene discussed is SGCB; the disease is systemic sclerosis.